A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
Recruiting
Phase 2
Interventional Study
The First Affiliated Hospital of Nanchang University
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 31 (estimated)
- Sponsor
- Shandong Cancer Hospital and Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Newly diagnosed Double Expression Diffuse Large B-cell Lymphoma
* Age 18-70 years
* ECOG performance status 0-2
* Ann Arbor stage II-IV
* 8.Subjects who in line with the testing standard of the clinical trial laboratory
* Life expectancy ≥ 3months
Exclusion Criteri…